17:46:17 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-06-05 Bokslutskommuniké 2025
2025-03-14 Kvartalsrapport 2025-Q3
2024-12-12 Kvartalsrapport 2025-Q2
2024-09-10 Årsstämma 2025
2024-09-06 Kvartalsrapport 2025-Q1
2024-06-05 Bokslutskommuniké 2024
2024-03-08 Kvartalsrapport 2024-Q3
2023-12-15 Kvartalsrapport 2024-Q2
2023-10-09 Inlösen SECT B 1.1
2023-09-08 Ordinarie utdelning SECT B 0.00 SEK
2023-09-07 Årsstämma 2024
2023-09-05 Kvartalsrapport 2024-Q1
2023-06-02 Bokslutskommuniké 2023
2023-03-10 Kvartalsrapport 2023-Q3
2022-12-16 Kvartalsrapport 2023-Q2
2022-10-10 Inlösen SECT B 1
2022-09-09 Ordinarie utdelning SECT B 0.00 SEK
2022-09-08 Årsstämma 2023
2022-09-02 Kvartalsrapport 2023-Q1
2022-06-03 Bokslutskommuniké 2022
2022-03-09 Kvartalsrapport 2022-Q3
2021-12-10 Kvartalsrapport 2022-Q2
2021-10-18 Inlösen SECT B 0.9
2021-09-24 Split SECT B 1:5
2021-09-15 Ordinarie utdelning SECT B 0.00 SEK
2021-09-14 Årsstämma 2022
2021-09-03 Kvartalsrapport 2022-Q1
2021-06-02 Bokslutskommuniké 2021
2021-03-12 Kvartalsrapport 2021-Q3
2020-11-27 Kvartalsrapport 2021-Q2
2020-10-05 Inlösen SECT B 4.5
2020-09-09 Ordinarie utdelning SECT B 0.00 SEK
2020-09-08 Årsstämma 2021
2020-09-04 Kvartalsrapport 2021-Q1
2020-06-03 Bokslutskommuniké 2020
2020-03-04 Kvartalsrapport 2020-Q3
2019-11-28 Kvartalsrapport 2020-Q2
2019-10-02 Inlösen SECT B 4.5
2019-09-06 Ordinarie utdelning SECT B 0.00 SEK
2019-09-05 Årsstämma 2020
2019-09-03 Kvartalsrapport 2020-Q1
2019-05-28 Bokslutskommuniké 2019
2019-03-06 Kvartalsrapport 2019-Q3
2018-12-07 Kvartalsrapport 2019-Q2
2018-10-03 Inlösen SECT B 4.5
2018-09-07 Ordinarie utdelning SECT B 0.00 SEK
2018-09-06 Årsstämma 2019
2018-09-04 Kvartalsrapport 2019-Q1
2018-05-29 Bokslutskommuniké 2018
2018-03-12 Kvartalsrapport 2018-Q3
2017-12-08 Kvartalsrapport 2018-Q2
2017-10-02 Inlösen SECT B 4.5
2017-09-14 Ordinarie utdelning SECT B 0.00 SEK
2017-09-13 Årsstämma 2018
2017-09-12 Kvartalsrapport 2018-Q1
2017-05-30 Bokslutskommuniké 2017
2017-03-07 Kvartalsrapport 2017-Q3
2016-12-07 Kvartalsrapport 2017-Q2
2016-10-04 Inlösen SECT B 4.5
2016-09-07 Ordinarie utdelning SECT B 0.00 SEK
2016-09-06 Årsstämma 2017
2016-09-05 Kvartalsrapport 2017-Q1
2016-05-31 Bokslutskommuniké 2016
2016-03-08 Kvartalsrapport 2016-Q3
2015-12-08 Kvartalsrapport 2016-Q2
2015-09-28 Inlösen SECT B 4.5
2015-09-15 Kapitalmarknadsdag 2015
2015-09-08 Ordinarie utdelning SECT B 0.00 SEK
2015-09-07 Årsstämma 2016
2015-09-07 Kvartalsrapport 2016-Q1
2015-06-03 Bokslutskommuniké 2015
2015-03-10 Kvartalsrapport 2015-Q3
2014-12-09 Kvartalsrapport 2015-Q2
2014-09-25 Inlösen SECT B 4.5
2014-09-09 Ordinarie utdelning SECT B 0.00 SEK
2014-09-08 Kvartalsrapport 2015-Q1
2014-09-08 Årsstämma 2015
2014-05-27 Bokslutskommuniké 2014
2014-03-04 Kvartalsrapport 2014-Q3
2013-12-10 Kvartalsrapport 2014-Q2
2013-09-10 Kvartalsrapport 2014-Q1
2013-07-11 Inlösen SECT B 4.5
2013-06-28 Ordinarie utdelning SECT B 0.00 SEK
2013-06-27 Årsstämma 2013
2013-05-29 Bokslutskommuniké 2013
2013-05-28 Bokslutskommuniké 2012
2013-05-28 Analytiker möte 2013
2013-03-06 Kapitalmarknadsdag 2013
2013-03-05 Kvartalsrapport 2012-Q3
2012-12-04 Kvartalsrapport 2012-Q2
2012-09-04 Kvartalsrapport 2012-Q1
2012-07-12 Inlösen SECT B 5
2012-06-29 Ordinarie utdelning SECT B 0.00 SEK
2012-06-28 Årsstämma 2011
2012-05-22 Analytiker möte 2011
2012-05-21 Bokslutskommuniké 2011
2012-03-05 Kvartalsrapport 2011-Q3
2011-12-06 15-7 2011
2011-12-05 Inlösen SECT B 5
2011-12-04 Kvartalsrapport 2011-Q2
2011-11-23 Ordinarie utdelning SECT B 0.00 SEK
2011-11-22 Extra Bolagsstämma 2011
2011-09-04 Kvartalsrapport 2011-Q1
2011-05-24 Bokslutskommuniké 2010
2011-03-08 Kvartalsrapport 2010-Q3
2010-07-01 Ordinarie utdelning SECT B 0.00 SEK
2010-06-30 Årsstämma 2010
2010-05-25 Bokslutskommuniké 2009
2010-03-16 Kvartalsrapport 2009-Q3
2009-12-08 Kvartalsrapport 2009-Q2
2009-09-14 Kvartalsrapport 2009-Q1
2009-06-29 Ordinarie utdelning SECT B 0.00 SEK
2009-06-26 Årsstämma 1
2008-06-26 Ordinarie utdelning SECT B 0.50 SEK
2007-06-29 Ordinarie utdelning SECT B 0.50 SEK
2006-06-29 Ordinarie utdelning SECT B 0.50 SEK
2000-08-11 Split SECT B 1:3

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Sectra är verksamt inom säkerhetslösningar. Störst affärsinriktning återfinns inom medicinteknik och cybersäkerhet. Bolaget utvecklar IT-lösningar som används bland sjukhus, institut och myndigheter på global nivå för hantering av kritisk infrastruktur samt känslig datainformation. Störst verksamhet återfinns inom den europeiska marknaden, där lösningarna säljs via flertalet dotterbolag. Sectra grundades 1978 och har sitt huvudkontor i Linköping.
2024-04-29 13:00:00

Linköping, Sweden - April 29, 2024 - International medical imaging IT and Cybersecurity company Sectra's (https://sectra.com/) (STO: SECT B) digital pathology solution together with Leica Biosystems, Imaging, Inc.'s Aperio GT 450 DX have received a 510(k) clearance by the US Food & Drug Administration (FDA). This is the first time an FDA clearance within digital pathology allows the use of DICOM images for pathology diagnostics, which marks a significant step towards standardization in this field.

Sectra received its first FDA clearance during the pandemic, in 2020. The pandemic made the need and value of remote work even in the field of pathology obvious and has helped boost the adoption of digital pathology in the US. Today, the value of accessing, sharing and reviewing digital images is clear and the market for digital pathology in the US, as well as other countries, is growing rapidly. 

"Given the rigorous review and clearance process leading up to this point, I see the new FDA clearance as strong proof of the quality of our solution. It is also an enabler for pathology departments to benefit from the latest scanner technology as well as the standardization that is happening within digital pathology. We have already seen how our customers utilize digital pathology to improve patient care, especially in complex cases such as cancer, and I am proud to be part of that journey," says Elin Kindberg, Global Product Manager Pathology at Sectra.

The FDA clearance includes:
  • Sectra's digital pathology solution when used with Leica Biosystems Aperio GT 450 DX  
  • SVS and DICOM file formats 
  • Sectra UniView and IDS7
  • cloud-based and on-premises installation

"Sectra has a strong track record of promoting and enabling open integrations and of pushing the development towards standardization within medical imaging IT. The recent FDA clearance including the clearance to utilize DICOM images for pathology diagnostics therefore makes me very proud. Due to the unique nature of the images used in digital pathology, proprietary formats have previously dominated. This FDA approval, including DICOM, shows that standardization is possible also within pathology. This is an important first step to a reality where healthcare providers can start reaping the benefits of a larger degree of freedom in choosing what hardware and software to combine, within pathology. This has the potential to increase workflow efficiency, facilitate the adoption of new technology and in the end-benefit patient care," says Dr. Torbjörn Kronander, CEO and President Sectra AB.

A digital pathology solution provides instant and, if necessary, remote access to digital images of tissue samples instead of relying on physical glass slides reviewed in microscopes. This optimizes the workflows for pathologists, leading to enhanced efficiency in cancer diagnostics. Learn more about Sectra's digital pathology solution >> (https://www.youtube.com/watch?v=g_oXh4kp770)

The pathology solution is part of Sectra's enterprise imaging solution, which provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra's website to read more about Sectra and why it's top-ranked in "Best in KLAS (https://medical.sectra.com/about-sectra/sectra-pacs-best-in-klas/)".

About Sectra
Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2022/2023 fiscal year totaled SEK 2,351 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra's website (https://sectra.com/).